0001140361-23-039417.txt : 20230814 0001140361-23-039417.hdr.sgml : 20230814 20230814081043 ACCESSION NUMBER: 0001140361-23-039417 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230811 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bionano Genomics, Inc. CENTRAL INDEX KEY: 0001411690 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 261756290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38613 FILM NUMBER: 231166441 BUSINESS ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Bionano Genomics, Inc DATE OF NAME CHANGE: 20190308 FORMER COMPANY: FORMER CONFORMED NAME: BioNano Genomics, Inc DATE OF NAME CHANGE: 20120703 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 8-K 1 brhc20057474_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 11, 2023
 
Bionano Genomics, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-38613
26-1756290
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

9540 Towne Centre Drive, Suite 100
San Diego, California
  
92121
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (858) 888-7600
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
BNGO
The Nasdaq Stock Market, LLC
Warrants to purchase Common Stock
BNGOW
The Nasdaq Stock Market, LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Financial Officer

On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.’s (the “Company”) Chief Financial Officer, effective as of September 11, 2023 (the “Effective Date”).

Ms. Kama, 50, most recently served as the Chief Financial Officer of Northern Data AG beginning in June 2022. Prior to joining Northern Data, Ms. Kama served as the Chief Financial Officer of the East Region and Healthcare IT for Quest Diagnostics Incorporated from May 2016 to May 2022.

Pursuant to the terms of Ms. Kama’s employment agreement (the “Kama Employment Agreement”), effective as of the Effective Date, Ms. Kama’s employment may be terminated at-will by either party, with or without notice, subject to the terms of the Kama Employment Agreement. Ms. Kama will receive a base salary of $460,000 per year and be eligible for an annual discretionary bonus with a target amount of 55% of her base salary based on the achievement of certain performance goals that are determined by the Board of Directors of the Company. Ms. Kama will be issued an option to purchase 106,000 shares of common stock in the Company with a per share exercise price equal to the fair market value on the date of grant (the “Option”). The shares subject to the Option will vest over four years of continuous service to the Company, with 25% of the shares subject to the Option vesting on the first year anniversary of the Effective Date, and the remaining shares vesting in equal monthly installments over the subsequent 36 months of continuous service thereafter. The Option shall be governed in all respects by the terms of the Company’s 2020 Inducement Plan, as amended, and option agreement between Ms. Kama and the Company. Ms. Kama will also receive a one-time signing bonus of $150,000 contingent on Ms. Kama remaining continuously employed with the Company for one year after the Effective Date.

Ms. Kama will be entitled to receive severance benefits in the event her employment is terminated by the Company without cause or she resigns for good reason, provided she remains in compliance with the terms of the Kama Employment Agreement. In the event of such termination or resignation, Ms. Kama will receive (i) severance in a lump sum equal to six months of her then-current base salary, (ii) up to six months of COBRA group health insurance continuation, and (iii) any unvested portion of the Option, but only if such termination is during the period beginning 30 days before and ending 24 months following a change in control. The severance benefits are conditioned upon Ms. Kama signing and not revoking a separation agreement and release of claims by no later than the 45th day after the employment termination.

The Company expects that Ms. Kama will enter into the Company’s standard form of indemnification agreement, a form of which was filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-225970), filed with the SEC on July 17, 2018.

The selection of Ms. Kama to serve as the Company’s Chief Financial Officer was not pursuant to any arrangement or understanding with respect to any other person. In addition, there are no family relationships between Ms. Kama and any director or executive officer of the Company. Ms. Kama has not been a party to any transaction with the Company or its subsidiaries of the type required to be disclosed pursuant to Item 404(a) of Regulation S-K, and no such transaction is currently contemplated.

The foregoing description of the Kama Employment Agreement is not complete and is subject to and qualified in its entirety by reference to the complete text of the Kama Employment Agreement, a copy of which the Company intends to file with the Securities and Exchange Commission (“SEC”) as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2023.

Departure of Chief Financial Officer

On August 11, 2023, Christopher Stewart resigned as Chief Financial Officer of the Company effective as of September 11, 2023. Following the Effective Date and to ensure an orderly transition, Mr. Stewart has agreed to consult with the Company through November 11, 2023, which may be further extended with the mutual agreement of Mr. Stewart and the Company (the “Consulting Period”).

In connection with Mr. Stewart’s resignation, the Company and Mr. Stewart entered into a transition, separation and consulting agreement (the “Stewart Separation and Consulting Agreement”) pursuant to which Mr. Stewart: (i) will continue in employment with the Company through the Effective Date, unless terminated sooner, (ii) will be entitled to receive, subject to Mr. Stewart’s execution of a customary release of claims in favor of the Company and compliance with his obligations under the Separation and Consulting Agreement: (a) a lump sum amount equal to six weeks of his current annual base salary as a transition period bonus payment; (b) a lump sum amount equal to six weeks of his current annual base salary upon achievement of a strategic milestone on or before September 11, 2023; (c) a cash amount equal to six months of his current annual base salary; and (d) COBRA group health insurance continuation up to February 29, 2024, (iii) will be eligible to be paid by the Company consulting fees at a rate of $500.00 per hour for actual time spent providing consulting services to the Company during the Consulting Period, and (iv) will have his equity awards continue to vest through the end of the Consulting Period.

The foregoing description of the Stewart Separation and Consulting Agreement is not complete and is subject to and qualified in its entirety by reference to the complete text of the Stewart Separation and Consulting Agreement, a copy of which the Company intends to file with the SEC as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2023.

Item 7.01
Regulation FD Disclosure.

On August 14, 2023, the Company issued a press release announcing Ms. Kama’s appointment and Mr. Stewart’s departure. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01 and the related exhibit are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.
Description
99.1
104
Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Bionano Genomics, Inc.
     
Date: August 14, 2023
By:
  
/s/ R. Erik Holmlin, Ph.D.
     
R. Erik Holmlin, Ph.D.
     
President and Chief Executive Officer
(Principal Executive Officer)


EX-99.1 2 brhc20057474_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

SAN DIEGO, August 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role.
 
Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northern Data AG, Ms. Kama was Chief Financial Officer, East Region and Healthcare IT at Quest Diagnostics, Quest’s largest region, where she drove market expansion and operational efficiencies. Before Quest, Ms. Kama established an impressive track record of transformative and growth-oriented leadership across a diverse range of multibillion-dollar organizations, including FedEx, United Airlines, A&P, and AIG, where she held senior leadership roles in strategic planning, financial planning and analysis, capital planning and corporate strategy.
 
“I am pleased to welcome Gülsen to Bionano. We believe the combination of her track record managing financial strategy at global businesses, including Quest Diagnostics and United Airlines, combined with her experience helping scale startup Northern Data, make her well-suited to help Bionano continue transforming cytogenetics into a streamlined workflow in healthcare while charting a course toward profitability. Gülsen has decades of capital management experience at complex companies, where she helped improve efficiency and implemented cost controls, resulting in higher returns to shareholders. All of us on the senior leadership team are really looking forward to partnering with Gülsen as she helps propel us to reach new heights. We also extend our gratitude to Chris Stewart for his leadership in helping us transition out of the pandemic and build our growing business,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

About Bionano
 
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
 
Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano
 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “plan,” “potential,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations, including any potential benefits that may be realized as a result of new members of management. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and potential future bank failures, the ongoing Ukraine-Russian conflict, and related sanctions, and any global pandemics, on our business and the global economy; execution of our stated strategies and plans[delete extra space]; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
 
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com


 EX-101.SCH 3 bngo-20230811.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bngo-20230811_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bngo-20230811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock [Member] Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Warrants to purchase Common Stock [Member] EX-101.PRE 6 bngo-20230811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00003.jpg begin 644 image00003.jpg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end GRAPHIC 8 image00004.jpg begin 644 image00004.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 11, 2023
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2023
Entity File Number 001-38613
Entity Registrant Name Bionano Genomics, Inc.
Entity Central Index Key 0001411690
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-1756290
Entity Address, Address Line One 9540 Towne Centre Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 888-7600
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol BNGO
Security Exchange Name NASDAQ
Warrants to purchase Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Warrants to purchase Common Stock
Trading Symbol BNGOW
Security Exchange Name NASDAQ
XML 10 brhc20057474_8k_htm.xml IDEA: XBRL DOCUMENT 0001411690 2023-08-11 2023-08-11 0001411690 us-gaap:CommonStockMember 2023-08-11 2023-08-11 0001411690 bngo:WarrantsToPurchaseCommonStockMember 2023-08-11 2023-08-11 false 0001411690 8-K 2023-08-11 Bionano Genomics, Inc. DE 001-38613 26-1756290 9540 Towne Centre Drive Suite 100 San Diego CA 92121 858 888-7600 false false false false Common Stock, $0.0001 par value per share BNGO NASDAQ Warrants to purchase Common Stock BNGOW NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !500Y799!YDAD! #/ P $P M @ %!$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "+ %% ! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 23 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bionanogenomics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc20057474_8k.htm bngo-20230811.xsd bngo-20230811_def.xml bngo-20230811_lab.xml bngo-20230811_pre.xml brhc20057474_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20057474_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bngo-20230811_def.xml" ] }, "inline": { "local": [ "brhc20057474_8k.htm" ] }, "labelLink": { "local": [ "bngo-20230811_lab.xml" ] }, "presentationLink": { "local": [ "bngo-20230811_pre.xml" ] }, "schema": { "local": [ "bngo-20230811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bngo", "nsuri": "http://bionanogenomics.com/20230811", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc20057474_8k.htm", "contextRef": "c20230811to20230811", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://bionanogenomics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc20057474_8k.htm", "contextRef": "c20230811to20230811", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bngo_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase Common Stock [Member]" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://bionanogenomics.com/20230811", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001140361-23-039417-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-039417-xbrl.zip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end